Beta

Satellos bioscience inc. common stockMSLE.US Overview

US StockHealthcare
(No presentation for MSLE)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

MSLE AI Insights

MSLE Overall Performance

MSLE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MSLE Recent Performance

6.28%

Satellos bioscience inc. common stock

-1.10%

Avg of Sector

-0.49%

S&P500

MSLE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check MSLE's Trend

MSLE Key Information

MSLE Valuation Metrics

MSLE Profile

Price of MSLE

MSLE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MSLE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.24
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-8.71
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.24
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MSLE's latest earnings report released?

    The most recent financial report for Satellos bioscience inc. common stock (MSLE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MSLE's short-term business performance and financial health. For the latest updates on MSLE's earnings releases, visit this page regularly.

  • How much cash does MSLE have?

    At the end of the period, Satellos bioscience inc. common stock (MSLE) held Total Cash and Cash Equivalents of 9.8M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.